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The neuronal ceroid-lipofuscinoses (NCLs) are inherited lysosomal storage diseases and constitute the most common group of children's
progressive encephalopathies. Most childhood forms of NCL are clinically characterized by progressive loss of vision as well as mental and motor
deterioration, epileptic seizures, and premature death, while the rare adult forms are dominated by dementia. All forms of NCL share common
pathomorphological features. Autofluorescent, periodic acid-Schiff- and Sudan black B-positive granules, resistant to lipid solvents, accumulate in
the cytoplasm of most nerve cells, and there is progressive and remarkably selective neuronal degeneration and loss. For a long time, the NCLs
were grouped under the heading of the “amaurotic family idiocies” and conceived as lipidoses. However, in the late 1980ies and 1990ies the NCL
storage cytosomes were shown to consist largely of two hydrophobic proteins: either subunit c of mitochondrial ATP synthase or sphingolipid
activator proteins A and D. Since 1995 numerous mutations in at least seven different genes have been shown to underlie the multiple human and
animal forms of NCL. This review discusses the historical evolution of the NCL concept and the impact of the recent biochemical and molecular
genetic findings on our views on the classification and pathogenesis of these devastating brain disorders.
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The neuronal ceroid-lipofuscinoses (NCLs, also referred to
as Batten's disease) [90] are inherited lysosomal storage
diseases and collectively constitute the most common group
of children's progressive encephalopathies. Their overall
incidence in the US has been estimated at 1:12 500 [49], and
certain forms of NCL are relatively frequent in Northern
European populations [74]. In addition to the human NCLs, a
number of spontaneous animal forms of NCL have been
described, discussed in detail elsewhere in this issue.
The clinical and pathological features of the human NCLs
have been thoroughly reviewed in recent years [18,20,82].
With one exception, the NCLs show an autosomal recessive
mode of inheritance, and may have a congenital, infantile, late
infantile, juvenile or adult onset. Most childhood forms are
clinically characterized by progressive loss of vision as well as⁎ Tel.: +358 9 191 26337.
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doi:10.1016/j.bbadis.2006.06.010mental and motor deterioration, epileptic seizures and pre-
mature death, while the rare adult-onset forms are dominated
by dementia. Despite the varying clinical features, all forms of
NCL share unifying pathomorphological characteristics. Auto-
fluorescent, periodic acid-Schiff (PAS)- and Sudan black B-
positive granules, resistant to lipid solvents, accumulate in the
cytoplasm of most nerve cells (Fig. 1) and, to a lesser extent,
of many other cell types. There is progressive and remarkably
selective neuronal loss, coupled with astrocytic proliferation
and hypertrophy as well as macrophage infiltration. In the most
severe congenital and infantile NCLs the cortical and retinal
neurons may be almost completely destroyed, resulting in
extreme brain and retinal atrophy. The ultrastructure of the
accumulating storage cytosomes varies between the different
forms of NCL [13] (Fig. 2) and has long served as the basis of
their classification, along with the age of clinical onset
[18,20,82].
The biochemical nature of the materials accumulating within
the pathological autofluorescent cytosomes first began to be
understood in the late 1980ies [43,45,70], and the first genomic
defects causing NCL were identified in 1995 [1,79]. Since then,
Fig. 1. The intraneuronal storage material in all forms of neuronal ceroid-lipofuscinosis shows autofluorescence in ultraviolet light, seen here as moon-like crescents
around the nuclei of cortical neurons (A). The storage granules stain positively with Luxol fast blue (B), periodic acid-Schiff (C) and Sudan black B (D) methods.
Paraffin sections from the cerebral cortex of a patient with CLN5 ×300 (A) and CLN8 ×1000 (B–D). Reproduced with permission from the Journal of Neuropathology
and Experimental Neurology.
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purpose of this paper is to review the historical development of
the NCL concept and to discuss the impact of the recent
molecular findings on our views on the classification and
pathogenesis of these devastating brain disorders.
2. The first clinical description
The credit for the first clinical description of any form of
NCL is usually given to Dr. Otto Christian Stengel, physician at
the Copper Mining Company of Røros, a small Norwegian
town. His “Account of a singular illness among four siblings in
the vicinity of Røraas” (Fig. 3) was published in the first volume
of the first Norwegian medical Journal in 1826 [66] and coupled
systematic clinical observation with scientific thinking. The
four consecutive children, two boys and two girls, of apparently
healthy parents did well until the age of 6 years when their sight
began to deteriorate. Within years, the disease led to blindness,
progressive mental deterioration and loss of speech, epileptic
fits, and premature death (by the time of publication the two
oldest siblings had died at the ages of 21 and 20 years). No
autopsies were performed. Stengel's report, written in Norwe-Fig. 2. The ultrastructural appearances of the intraneuronal storage deposits vary betw
can be delineated: (A) granular osmiophilic deposits are characteristic of the infan
classic late infantile neuronal ceroid-lipofuscinosis CLN2, ×20,000; (C) fingerprint p
CLN3, ×30,000; (D) many inclusions in the variant forms of late infantile neu
Reproduced with permission from the Journal of Neuropathology and Experimentagian, remained unnoticed until attention was brought to its
significance by his countrymen more than a century later.
3. “The amaurotic family idiocies”
The concept of “amaurotic family idiocy” [51] was created
by the American neurologist Sachs, based on his observations
in a set of siblings of rapidly progressive loss of vision,
combined with severe mental retardation of infantile onset. The
disease was morphologically characterized by accumulation of
material of lipid nature within markedly ballooned nerve cells
of the central nervous system. Between the years 1903 and
1914 a number of further patients with progressive loss of
vision and psychomotor retardation but with a later onset were
described in a familial setting. Patients with both late infantile
and juvenile onset were reported by Batten [3,4] and Vogt [83–
85], patients with a juvenile onset by Spielmeyer [63–65], and
patients with late infantile onset by Janský [29] and
Bielschowsky [6]. At neuropathological autopsy, all these
further patients showed accumulation within nerve cells of
granular material with lipid-like staining qualities. Inspired by
the clinical similarities (familial occurrence, progressive loss ofeen the different forms of the neuronal ceroid-lipofuscinoses. Four basic types
tile and other forms of CLN1, ×10,000; (B) curvilinear profiles are typical of
atterns are the predominant type of intraneuronal inclusions in the juvenile form
ronal ceroid-lipofuscinosis correspond to the rectilinear complex, ×15,000.
l Neurology.
Fig. 3. The first page of Dr. Otto Christian Stengel's original clinical description
of juvenile NCL in the first volume of the first Norwegian medical journal “Eyr”
in 1826.
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concept of intraneuronal “thesaurismosis” [59,60] or “storage”,
all these familial cases were gradually lumped together and
considered to represent variants of “amaurotic family idiocies”
of either infantile (Tay–Sachs), late-infantile (Janský–
Bielschowsky), or juvenile (Spielmeyer–Sjögren) onset. In
1925 Kufs published his first report on familial adult onset
intellectual deterioration with similar neuropathological fea-
tures but without loss of vision [35]. Klenk's biochemical
studies in 1939 [33] showed an increased cerebral ganglioside
concentration in the infantile Tay–Sachs form of “amaurotic
family idiocy”, and in 1962 Svennerholm identified the major
storage material in this disease as GM2-ganglioside [67].
However, he also confirmed Klenk's observation that there
was no increase in the amount of gangliosides in the juvenile
form of “amaurotic family idiocy”.
4. The neuronal ceroid-lipofuscinoses
Klenk's and Svennerholm's studies already indicated that the
group of the “amaurotic family idiocies” was biochemically
heterogeneous. Furthermore, comparative histochemical and
electron microscopic studies in the early 1960ies demonstrated
that the intraneuronal storage cytosomes in the juvenile
Spielmeyer–Sjögren form of “amaurotic family idiocy” [88]
radically differed from the membraneous cytoplasmic bodies
found in the infantile Tay–Sachs form [68] and were close to the
autofluorescent “lipopigments” ceroid and lipofuscin [88,89]. In
contrast to the storage material in the infantile Tay–Sachs type
of “amaurotic family idiocy”, the storage cytosomes in the late
infantile and juvenile cases were largely resistant to lipid
solvents and showed a characteristic curvilinear (late infantile)
or fingerprint (juvenile) pattern [88,89]. In order to clearly
distinguish the late infantile and juvenile forms of the
“amaurotic family idiocy” and the histochemically similar
Kuf's adult onset disease from Tay–Sachs disease and other
gangliosidoses, Zeman and Dyken [90] proposed the new term
neuronal ceroid-lipofuscinosis (NCL), based on the histochem-ical and electron microscopic characteristics of the storage
material. After inclusion of a new infantile type of NCL,
described by Haltia et al. [21,22] and Santavuori et al. [55] and
characterized by storage cytosomes with a finely granular
ultrastructure (granular osmiophilic deposits or GRODs), and
the first animal form of NCL in English setters [34], a new
classification of the NCLs was proposed [87], essentially based
on the age of clinical onset and the ultrastructure of the storage
cytosomes. Four different types of human NCL and a canine
form were distinguished. The human forms of NCL included
the infantile (Haltia–Santavuori), late infantile (Janský–
Bielschowsky, juvenile (Spielmeyer–Sjögren) and the adult
(Kufs) types [87]. This classification did not pay attention to the
occasional congenital cases reported earlier [11,41,53]. With
time, a number of “atypical” or “variant” cases were reported,
often with a late infantile/early juvenile onset [37,56,57,72,81],
expanding the spectrum of human NCLs further. Surprisingly,
even Northern epilepsy, an inherited childhood epilepsy
syndrome with relatively mild and protracted mental retardation
[26], turned out to be a novel form of NCL at neuropathological
analysis [23,25]. New forms of spontaneous NCL were also
discovered in many breeds of dogs [32], as well as in cats
[7,19,39,77], sheep [12,30,31], goats [15], cattle [24,48], horses
[73], and mice [9,10].
5. Classification based on storage materials
The ovine models turned out to be important in the further
development of the NCL concept. Isolation and biochemical
analysis of the storage cytosomes in New Hampshire sheep
showed that they were largely composed of protein, not lipid
[43]. The main component was identified as subunit c of the
mitochondrial ATP synthase [14,45], soon found as the major
stored protein also in most other animal and human types of
NCL [44]. However, purification and protein chemical studies
of the storage cytosomes in the human infantile type of NCL
established sphingolipid activator proteins (saposins) A and D
as their main protein components [70]. Subsequently, sphingo-
lipid activator proteins were also discovered as the predominant
protein component of the storage material in the miniature
Schnauzer dog model [46], the congenital ovine model [71], and
the congenital human NCL [61]. Consequently, the human and
animal forms of NCL can now be classified into two main
categories, based on the chemical identity of the predominant
storage protein: those storing subunit c and those storing
sphingolipid activator proteins A and D (Table 1). The principle
stored compound seems to determine the ultrastructure of the
storage cytosomes. Storage of sphingolipid activator proteins
has invariably been associated with GRODs, while storage of
subunit c has been associated with more variable electron
microscopic appearances (curvilinear, rectilinear or fingerprint
patterns).
6. Molecular genetic classification
The first NCL gene, responsible for the infantile form of
NCL, was identified by a positional candidate gene approach in
Table 1









CLN1 Haltia - Santavuori [22,55] 256,730 INCL (LINCL, JNCL, ANCL) GROD 1p32 CLN1 [79] PPT1 SAPs
CLN2 Janský-Bielschowsky [6,29] 204,500 LINCL CL 11p15 CLN2 [62] TPP1 SCMAS
CLN3 Spielmeyer-Sjögren
[3,4,63–65,84]
204,200 JNCL FP (CL, RL) 16p12 CLN3 [1] CLN3 SCMAS
CLN4 Kufs [35] 204,300 ANCL FP, granular ? ? ? SCMAS
CLN5 vLINCL Finnish [56,57,72] 256,731 vLINCL RL, CL, FP 13q22 CLN5 [58] CLN5 SCMAS
CLN6 Lake-Cavanagh [37] 601,780 vLINCL (early juvenile) RL, CL, FP 15q21–23 CLN6 [16,80] CLN6 SCMAS
CLN7 vLINCL Turkish [81] – vLINCL RL, FP ? ? ? SCMAS
CLN8 Northern epilepsy [23,25,26] 600,143 EPMR, vLINCL CL-like, granular 8p32 CLN8 [47] CLN8 SCMAS
Congenital NCL Congenital NCL [11,41,53] – Congenital NCL GROD 11p15.5 CTSD [61] Cathepsin D SAPs
Parry disease Parry [8,40] 162,350 ANCL (autosomal dominant) GROD ? ? ? SAPs
Abbreviations: INCL, LINCL, vLINCL, JNCL and ANCL, infantile, late infantile, variant late infantile, juvenile and adult onset neuronal ceroid-lipofuscinosis;
EPMR, epilepsy with progressive mental retardation; GROD, granular osmiophilic deposits; CL, curvilinear profiles; FP, fingerprint bodies; RL, rectilinear profiles;
SCMAS, subunit c of mitochondrial ATP synthase; SAPs, sphingolipid activator proteins.
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soluble lysosomal enzyme. In the very same year, collaboration
of five research groups also led to the isolation, by positional
cloning, of the gene behind juvenile NCL, encoding a novel
putative membrane protein [1]. Since 1995 five further genes
[16,47,58,61,62,71,80] and an ever increasing number of
mutations responsible for human and/or animal forms of NCL
have been identified, now listed in a mutation database at www.
ucl.ac.uk/ncl. As a consequence, the human NCLs are now
classified into eight main genetic forms (CLN1–8)
[18,20,27,69], based on the number of hitherto predicted
genetic loci (Table 1). A few rare forms of NCL, including
the congenital [2,17,28] and dominantly inherited adult onset
NCL (Parry disease) [8,40], still remain without proper genetic
assignment (Table 1).
It is important to keep in mind that different mutations in a
single gene may give rise to different clinical phenotypes,
including different ages at onset, depending on the exact site
and type of the mutation. Common mutations that predominate
in a given form of NCL are usually associated with the “classic”
clinical picture, while rare “private” mutations may result in a
deviant phenotype. CLN1 may serve as an example in this
respect. Although the storage cytosomes of all CLN1 patients
so-far reported have shared the same ultrastructural pattern
(granular osmiophilic bodies), the clinical onset of the disease
has varied from infantile to late-infantile, juvenile [54] or even
adult [76]. Mutations associated with the “classic” severe
infantile phenotype are located close to the active site (Ser 155)
of the gene product PPT1 and profoundly disturb the structure
and function of the enzyme. In contrast, mutations resulting in
late-onset forms of CLN1 are remote from the catalytic triad,
leading only to limited changes in protein structure [5,52].
7. Pathogenetic hypotheses
For a long time the different forms of NCL were conceived
as lipidoses, along with Tay–Sachs disease, the prototype of the
“amaurotic family idiocies”. Analyses of the storage material
were believed to provide answers as to their exact etiopatho-
genesis. However, in contrast to Tay–Sachs disease, noganglioside accumulation could be demonstrated in brain tissue
[33,67,88], and the NCLs finally had to be separated from the
gangliosidoses [90]. The histochemical similarity of the NCL
storage cytosomes to the “lipopigments” ceroid and lipofuscin
[88,90] prompted the next main hypothesis. It was proposed that
the basic defect was the formation of pathological “lipopig-
ments”, possibly due to an increased rate of polyunsaturated
fatty acid peroxidation [86]. However, despite numerous
experimental and clinical studies, including treatment of
patients with various antioxidants, no conclusive evidence
could be presented in favor of this idea. The final blow to the
lipidosis concept came by the demonstration of proteins, either
subunit c of the mitochondrial ATP synthase [14,45] or
sphingolipid activator proteins [70], as the major components
of the purified NCL storage cytosomes.
Molecular genetic linkage studies, based on families of NCL
patients, carefully diagnosed by clinical and neuropathological
methods, finally led to the identification of seven genes and
over 150 different mutations behind the various forms of human
NCL. Apart from cathepsin D, first identified as responsible for
the congenital ovine model [71] and later for congenital human
NCL [61], all the NCL genes so far isolated in animals have
turned out to be homologues of previously established human
NCL genes. The products of the CLN1 and CLN2 genes, PPT1
and tripeptidyl peptidase 1 (TPP1), are soluble lysosomal
enzymes as is cathepsin D, an aspartyl proteinase, whereas the
CLN 3, CLN6, CLN8 and, possibly, CLN5 are transmembrane
proteins with still largely unknown functions (see [36]).
The newly discovered genetic heterogeneity of the NCLs
contrasts sharply with their remarkably uniform morphological
phenotype, the very basis of the whole NCL concept. How can
defects in these seven seemingly disparate genes lead to
essentially the same end result: intraneuronal accumulation of
certain hydrophobic proteins, coupled with highly selective
neuronal degeneration and death? So far, the mechanisms of
accumulation of subunit c of mitochondrial ATP synthase and
sphingolipid activator proteins and their relation, if any, to the
depletion of neurons remain unsolved. Likewise, although both
apoptotic [38,50] and excitotoxic [75] mechanisms have been
proposed, the deranged metabolic pathways leading to neuronal
854 M. Haltia / Biochimica et Biophysica Acta 1762 (2006) 850–856degeneration and death in NCL remain to be elucidated. The
uniform neuropathological features of the NCLs suggest the
existence of a common final pathogenetic pathway. Recent
observations of physical interactions of the CLN5 protein with
CLN2 and CLN3 [78] provide some experimental support in
favor of this idea. The existence of both human and ovine
congenital forms of NCL as well as recent experimental data
from the New Hampshire sheep model [42] show that the
pathogenic events may begin already at an early stage of fetal
development.
In conclusion, studies of the multiple human and animal
forms of NCL have so far identified a set of seven largely novel
genes whose defects result in selective degeneration and loss of
central nervous system neurons. It is evident that the metabolic
pathways involved are of vital importance for the survival of
neurons and that their identification will deepen our under-
standing of aging, neurodegeneration and neurodegenerative
disorders in general.
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